The on-cycle panel tells you whether the protocol is running within expected parameters. The post-cycle panel tells you whether the body is returning to homeostasis. The second question carries more long-term weight than the first — and is the one most commonly skipped.
Recovery is not a single-variable return to baseline testosterone. Recovery is the coordinated resumption of central HPTA signalling (LH pulse pattern, FSH secretion), testicular response (Leydig-cell testosterone synthesis, Sertoli-cell spermatogenesis), and downstream homeostasis (lipid normalisation, HCT descent, hepatic enzyme clearance if orals were used). Any one of these can stall independently. Only a full panel detects stalls that a serum testosterone reading alone would miss.
The research framework around anabolic steroid-induced hypogonadism (ASIH) and recovery is well-documented in the urology literature. Coward et al. 2013, J Urology — “Anabolic steroid induced hypogonadism in young men” — established the clinical syndrome and recovery patterns. Tatem et al. 2020, Translational Andrology and Urology reviewed pharmacological recovery interventions including SERM, hCG, and combined approaches. Rasmussen et al. 2016, J Clin Endocrinol Metab documented persistent endocrine dysfunction in former AAS users — the data underpinning why recovery monitoring matters beyond the immediate post-cycle window.
Recovery Timeline — Moderate 500 mg/week Testosterone Cycle, 12 Weeks, Standard SERM PCT
Week 2–3 post-PCT — early checkpoint. Most users show partial recovery: LH and FSH detectable and climbing, total testosterone in the 200–400 ng/dL range. Too early to draw firm conclusions; useful for detecting complete non-response (LH still undetectable at week 3 is a flag for extended pituitary suppression).
Week 6–8 post-PCT — the decision panel. Run the full baseline panel. Liver enzymes should be back to baseline. Lipids should be recovering (HDL climbing toward pre-cycle value). Testosterone should be in the 400–700 ng/dL range. Sensitive estradiol should be in the upper half of male reference. LH and FSH in normal range. HCT descending toward baseline. This is the panel that determines whether the user is cleared for the next protocol or requires extended recovery intervention.
Week 12 post-PCT — the stall checkpoint. If total testosterone is still <350 ng/dL with normal or low LH, recovery has stalled. This is the threshold for clinical input — not a “push through” moment. Coward 2013 described the structured intervention sequence for prolonged secondary hypogonadism: repeated SERM courses (clomiphene or enclomiphene), hCG add-back at 1500–3000 IU EOD × 4 weeks, and in resistant cases selective LH analogue therapy or formal TRT initiation. The condition does not reliably self-resolve past the 12-week mark without intervention; users who “wait it out” past 6 months frequently end up on permanent TRT having lost the recoverable window.
What Full Recovery Looks Like on Paper
Total testosterone — within 20% of pre-cycle baseline. Baseline 600 → recovered 480+ is within tolerance. Baseline 600 → recovered 320 is incomplete.
Free testosterone — tracks total unless SHBG has shifted. SHBG commonly rebounds upward post-PCT, an artefact of hepatic recalibration after clearance of exogenous androgens (the suppressive effect of supraphysiological testosterone on SHBG synthesis reverses). Elevated SHBG can produce normal total T with persistently low free T for 4–8 weeks post-recovery — the “low libido despite normal testosterone” pattern often resolves here once SHBG normalises.
LH — 1.7–8.6 mIU/mL reference. Detectable with pulsatile pattern is the functional recovery marker, not a single reading. Veldhuis et al. 2013, J Clin Endocrinol Metab reviewed pulsatile LH secretion as the operative central signal — single-point LH measurement underrepresents the recovery state.
FSH — 1.5–12.4 mIU/mL reference. Tends to recover slower than LH because Sertoli-cell feedback (via inhibin B) responds more slowly. Full spermatogenesis recovery trails serum normalisation by 3–6 months. Per de Souza & Hallak 2011, BJU International review of fertility outcomes in AAS-using men, sperm count recovery is the slowest-resolving variable post-cessation, with median 4 months for return to baseline in users without persistent testicular damage.
Estradiol — in male reference range on sensitive assay (10–40 pg/mL). Post-PCT E2 below 20 pg/mL is common and produces the classic iatrogenic hypoestrogenaemia syndrome users often misattribute to ongoing shutdown. It is usually SERM overshoot — clomiphene’s zuclomifene isomer accumulates across the 4-week course (half-life 14+ days) and can produce sustained E2 suppression. Resolves within 4 weeks of SERM discontinuation in most cases.
HDL — within 10% of baseline. 6–8 weeks for the median user; longer if oral compounds were used. Hartgens & Kuipers 2004 review documented full HDL recovery within 12 weeks of cessation in most cohorts.
LDL and ApoB — return to baseline within 4–6 weeks.
Liver enzymes (ALT, AST, GGT, ALP) — within reference range. 4 weeks is typical if the oral portion was ≤6 weeks; longer oral exposure or harsher compounds (oxymetholone, methyltestosterone) extend the recovery to 8–12 weeks.
HGB and HCT — descending if they were elevated on cycle. Complete normalisation within 8–12 weeks without phlebotomy in the majority of users; longer if phlebotomy was used during cycle (the iron stores deplete and reticulocyte response slows).
Prolactin — reference range if elevated by 19-nor exposure. Cabergoline-treated users may show overshoot to low-normal in the immediate post-cycle window; resolves within 2–4 weeks of cabergoline cessation.
Common Failure Modes — Pattern Recognition
Low LH + low testosterone at 8 weeks (combined hypogonadotropic-hypogonadism pattern). Central signal has not restarted. Extend SERM protocol 4 weeks at standard or escalated dose; retest at week 12. If still suppressed, clinical workup for persistent secondary hypogonadism. Karavolos et al. 2015, Asian J Andrology reviewed the clinical management algorithm for ASIH including extended SERM protocols and hCG bridge interventions.
Normal LH + low testosterone (primary testicular failure pattern). Leydig-cell desensitisation from extended exposure, or in rare cases pre-existing testicular insufficiency unmasked by suppression. hCG protocol (1500 IU EOD × 2–4 weeks) may restore Leydig responsiveness; formal endocrinology referral warranted if response absent. This is the pattern most often associated with multi-year cycling without on-cycle hCG support.
Normal testosterone + persistent libido loss, mood depression. Check estradiol first. Low E2 from SERM overshoot is the single most common explanation. Normal T with sensitive E2 <20 pg/mL is the classic pattern; the symptom set overlaps almost entirely with low-T symptoms but the intervention is the opposite (allow E2 to recover, not push T higher).
Persistent lipid abnormalities past 12 weeks. Usually resolves by 16 weeks with diet and cardio intervention. Occasional stubborn cases reflect pre-existing dyslipidaemia unmasked rather than AAS-induced — worth reviewing family cardiovascular history and considering NMR LipoProfile to characterise the particle pattern at this point.
Elevated liver enzymes past 12 weeks. Rare but clinically significant. Not a “push through” situation. Full hepatology workup warranted including hepatitis B/C serology, autoimmune hepatitis panel, ferritin and iron studies (haemochromatosis), and abdominal ultrasound. May reflect drug-induced liver injury with prolonged recovery, or an unrelated finding unmasked by scrutiny.
Persistent erythrocytosis past 8 weeks (HCT >52% off-cycle). Rare but warrants OSA workup (intermittent nocturnal hypoxia is the most common non-AAS cause of persistent erythrocytosis in men), JAK2 mutation testing in unusual cases, and review of any concurrent EPO-elevating exposures.
The Most-Skipped Test, and Why It Matters Most
Users pre-test reliably, sometimes mid-cycle, then skip the post-cycle panel because subjective recovery feels complete. This is the highest-cost false economy in the protocol. A subjectively recovered user with incomplete HPTA restoration enters the next cycle on a compromised baseline — suppressed starting testosterone, compromised lipids, residual HCT elevation, underlying Leydig-cell damage that the next cycle will compound. The Rasmussen 2016 J Clin Endocrinol Metab data on former users showed that incomplete recovery between cycles is the dominant pattern producing persistent endocrine dysfunction in long-term AAS-using populations — not the cycles themselves, but the cumulative damage from inadequate inter-cycle restoration.
Rule: every cycle ends with bloodwork at week 6–8 post-PCT. Clean panel → cleared for next protocol. Incomplete panel → wait and retest, extend recovery interventions, do not initiate the next cycle on incomplete recovery. This rule has no exceptions that survive long-term scrutiny.
Long-Run Markers for Multi-Year Users
Coronary artery calcium (CAC) score — baseline at age 40 for long-term users, earlier with family history. Repeat every 5 years (low-risk) or every 2–3 years (moderate-risk). Detects subclinical atherosclerosis that clean bloodwork cannot. Greenland et al. 2018, JACC reviewed CAC’s predictive performance — outperforms standard risk calculators by a wide margin. The Baggish 2017 Circulation cohort used CAC to demonstrate accelerated coronary atherosclerosis in long-term AAS-using weightlifters; this is the imaging modality that catches the cardiovascular damage before clinical events.
Echocardiogram with diastolic function assessment — every 2–3 years. Baggish et al. 2017, Circulation documented left ventricular hypertrophy and diastolic dysfunction in long-term AAS users — these are the quiet cardiac findings that single ECGs miss. Tissue Doppler imaging (TDI) and global longitudinal strain are the sensitive parameters; standard echo without these may underdetect early dysfunction.
PSA (prostate-specific antigen) — annually at age 40+, baseline at any adult age. Trend matters more than single values; PSA velocity >0.75 ng/mL/year is the urology threshold for further workup regardless of absolute value.
DEXA scan — body composition and bone density every 3–5 years. The bone-density component matters specifically for users who have run aggressive AI protocols (crashed E2 produces measurable bone resorption acceleration); the body composition component documents the long-term lean-mass trajectory.
Annual full-body skin check — standard recommendation; AAS do not specifically elevate skin-cancer risk, but the population selects for outdoor training and occasional tanning exposure that does. Trenbolone-using populations show elevated rates of severe acne and acne-related skin pathology in user-reported data.
Annual carotid intima-media thickness (CIMT) ultrasound — for users with elevated CAC or strong family history. Non-invasive ultrasound assessment of carotid arterial wall thickness; tracks atherosclerotic progression in real-time at substantially lower cost than serial CAC.
The Defensible Long-Term Position
The long-term safety profile in the AAS research literature does not correlate with “taking less.” It correlates with “testing more, and acting on the results.” The Baggish, Kanayama, Pope, and Rasmussen cohorts of long-term users document the same pattern: cardiovascular morbidity and mortality cluster in users who failed to monitor or to respond to monitoring data, while users who maintained structured serial bloodwork and imaging across cycles show substantially better outcomes despite similar cumulative compound exposure.
The research-informed protocol: structured pre-cycle, week-6 on-cycle, and week-6-to-8 post-PCT bloodwork as the minimum cadence; CAC scoring at age 40 with repeat at 5-year intervals; echo at 2–3 year intervals once CAC is positive; intervention threshold based on trajectory and delta-from-baseline rather than single-point reference range comparison; willingness to defer or modify subsequent cycles when the recovery panel reveals incomplete restoration. This is the framework that the published cardiovascular outcomes literature supports as compatible with long-term health on multi-year AAS protocols.